Seres Therapeutics, Takeda & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

The FDA granted Seres Therapeutics' SER-287 orphan drug designation. SER-287 treats pediatric ulcerative colitis.

The FDA approved Ferring Pharmaceutical's Clenpiq, a low-volume colonoscopy prep solution.

Takeda appointed Toshio Fujimoto, MD, to serve as the general manager of the Health Innovation Park in Shonan, Japan.

More articles on gastroenterology:
GI leader to know: Dr. Essam Quraishi of Gastrointestinal & Liver Consultants
Stock market week-in-review for 5 large GI companies — Nov. 27 to Dec. 1
How AI is improving polyp detection

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months